Skip to content

A Comprehensive Report for decision making



Released - June 2022


Oncology Clinical Stage Drug Developers

First Intelligence Report to provide Complete Insights on Cancer Late Stage Drug Discovery and In-depth Insights on 1150 Active, well-funded Oncology Clinical Stage Companies, developing over 2800+ Active Cancer Targeting Molecules.

Report Covers all Aspects of Cancer Drug Development Intelligence


This Intelligence Report is designed to Identify Oncology Clinical Stage Drug Developer’s Drug Pipeline, Technologies, Management Expertise, Funding and Partnering capabilities. It clearly demark individual company’s clinical pipeline and its emerging early stage oncology research pipeline. 

Report clearly outlines Top Pharma Companie’s Oncology Pipeline with their emerging partnering preferences and inclination towards particular technology domain. Similarly figure out largest number of active mid and small size innovation driven pharma companies, thus provides clear and many uncharted M&A target companies/molecules landscape. 

At par with US and Europe, the Report covers largest number of active companies from Chinese & South Korea Region, thus provide an update on the emergence of this region in Oncology Drug Discovery. 

clinical Oncology drug intelligence 2022
largest coverage

providing intelligence at fingertips


Worldwide 33 Countries Covered. Largest Coverage Guaranteed

Drug developers

1009 Active Clinical Stage Oncology Companies Profiled. 

Molecules in Development
1 +

Individual Drug Mechanism of Action & Drug Target

Cancer Targets
1 +

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

intelligence supercharged

1400+ pages - full of insights

Prebuild Intelligence

identify Emerging Technologies and Molecules

  • Small Molecule : Kinase Inhibitors. (227 Clinical Stage Companies)
  • Small Molecule : Proteolysis Targeting Chimera (PROTACs). (22 Clinical Stage Companies)
  • Nanoparticles/Nanotechnology based Cancer Targeting Drugs. (42 Clinical Stage Companies)
  • Cellular Therapy: T Cell/CAR-T/CAR-NK & other Cell based Therapies. (168 Clinical Stage Companies)
  • Oncolytic Viruses pipeline in Early Stage Development. (51 Clinical Stage Companies)
  • Monoclonal Antibodies pipeline in Early Stage Development. (176 Clinical Stage Companies)
  • Bi-Specific & Multi Specific Antibodies pipeline in Early Stage Development.(78 Clinical Stage Companies)
  • Antibody Drug Conjugates pipeline in Early Stage Development. (64 Clinical Stage Companies)
  • Cancer Vaccines pipeline in Early Stage Development. (121 Clinical Stage Companies)
  • Microbiome based Cancer Targeting Drugs. (10 Clinical Stage Companies)
  • Knowledge Multiplier


    Clinical Oncology Drug Intelligence 2022
    Other Intelligence Sources
    Clinical Stage Oncology Drug Developers
    1150 Active Companies
    (Well Funded with complete Oncology Pipeline)
    600-800 Companies
    (with many inactive and other domain companies)
    Worldwide Coverage
    33 Countries Included
    (53% USA, 28% Europe, 14% Asia and 5% ROW)
    Mainly United States and Europe Covered
    Oncology Drugs in Development
    2800+ Onco Targeting Drugs in Active Development
    (Clinical & Preclinical Drugs, with their Targets and mechanism of Action)
    250 – 400 Onco Early Stage Drugs
    (mainly includes Clinical Stage molecules in development)
    Bio-Partnering Details
    1000+ Oncology Deals, with complete details.
    (Complete coverage on Oncology focused Deals, Funding & Partnering Activities; since company’s incorporation)
    Limited to Database / Resource Subscribed to.
    (Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).
    Single Step Connect
    Over 2500+ Key Decision Makers in 1150 Companies
    with valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available)
    No Customized Solution Available in Market
    (Needs months of hard team work to prepare authentic business development tool.

    Further Customization on This Report

    Launch Offer
    (Save $400 USD)
     Till 10 June 2022